C2B begins investigating the possibility of engineering viruses to attack pathological bacteria.

The concept of using bacteriophage to attack pathologic bacteria has gained renewed attention because of the threat of antibiotic resistant disease.  The global antibiotic market is expected to expand over $40 billion dollars, yet 50% - 60% of all hospital acquired infections are caused by antibiotic resistant bacteria, which highlights the industry's current investment in R&D activity. 

Historically, therapeutic bacteriophage were isolated by screening of samples from the environment.  Screening of samples and identification of potential therapeutic clones is a time consuming and costly approach to developing medicinal bacteriophage.  C2B is seeking support to develop a tool that can be used to produce a library of recombinant bacteriophage for panning against pathological bacterial targets drastically reducing the time and cost for identifying potential therapeutic clones..